Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD
PR Newswire —
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules...